Lagmitaf is an antiretroviral combination medication used for the treatment of HIV-1 infection. It typically contains Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate, three well-established antiviral agents that work together to suppress HIV replication, improve immune function, and prevent the progression of HIV-related disease. It is usually administered as a once-daily oral tablet for convenient and effective long-term management.

Mechanism of Action

1. Dolutegravir (DTG): An integrase strand transfer inhibitor (INSTI) that blocks the HIV enzyme integrase, preventing viral DNA from integrating into the host genome—an essential step in HIV replication.

2. Lamivudine (3TC): A nucleoside reverse transcriptase inhibitor (NRTI) that incorporates into viral DNA and stops chain elongation.

3. Tenofovir Disoproxil Fumarate (TDF): A nucleotide reverse transcriptase inhibitor (NtRTI) that further blocks the reverse transcriptase enzyme, preventing the virus from making new DNA.

   Uses

   • Treatment of HIV-1 infection in adults and adolescents.

   • Part of combination antiretroviral therapy (ART) to reduce viral load and increase CD4 cell counts.

   • Helps prevent HIV-related opportunistic infections and disease progression.

   • Used as a once-daily fixed-dose regimen for simplified treatment adherence.

     Adverse Effects

     • Headache, dizziness, fatigue

     • Nausea, vomiting, diarrhea

     • Trouble sleeping or vivid dreams

     • Mild rash